Bill Commons

TX SB 1122

died on adjournment

Relating to applicability of certain prescription drug insurance laws to health benefit plans and pharmacy benefit managers.

Texas · 89th Legislature (2025 Regular Session) · upper

Introduced
2025-02-06
Status date
Latest action
2025-04-09 — Not again placed on intent calendar
Bill type
bill
Last updated

Subjects

Sponsors

  • Schwertnerprimary
  • Florescosponsor
  • Hughescosponsor

Committees

Not provided by source.

Action timeline

  1. 2025-02-06

    Received by the Secretary of the Senate

    filing,introduction

  2. 2025-02-06

    Filed

    filing

  3. 2025-02-24

    Read first time

    introduction,reading-1

  4. 2025-02-24

    Referred to Health & Human Services

    referral-committee

  5. 2025-03-05

    Scheduled for public hearing on . . .

  6. 2025-03-05

    Considered in public hearing

  7. 2025-03-05

    Testimony taken in committee

  8. 2025-03-05

    Left pending in committee

  9. 2025-03-12

    Co-author authorized

  10. 2025-03-13

    Co-author authorized

  11. 2025-03-26

    Considered in public hearing

  12. 2025-03-26

    Vote taken in committee

  13. 2025-03-31

    Reported favorably w/o amendments

    committee-passage-favorable

  14. 2025-03-31

    Committee report printed and distributed

  15. 2025-04-03

    Placed on intent calendar

  16. 2025-04-09

    Not again placed on intent calendar

Versions

Documents

Votes

Not provided by source.

Related bills

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:33:51.767464Z

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=TX&identifier=SB 1122. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.
  • Some documents have no extracted text yet, so version comparison may be limited.

See the methodology page for data sources and limitations.